CA-MATRIXX-SOFTWARE
5.5.2021 02:04:09 CEST | Business Wire | Press release
MATRIXX Software , a global leader in 5G monetization for the communications industry, today announced it has partnered with Australia’s TPG Telecom Limited (ASX: TPG). TPG Telecom operates a number of leading mobile and internet brands including Vodafone, TPG, iiNet, AAPT, Internode and Lebara, providing consumers with a comprehensive portfolio of fixed and mobile products in the Australian telecommunications market.
With their 5G rollout progressing full steam ahead across major Australian cities, TPG Telecom is committed to cementing its place as a strong force for its customers. Looking ahead, as 5G becomes mainstream, TPG Telecom is seeking to unlock new opportunities and offerings resulting from the coming explosion of connected devices. With a goal to improve experience today, while laying the foundation for future innovation, TPG Telecom selected the MATRIXX Digital Commerce Platform to build a flexible, agile service capable of delivering real-time innovation to meet ever-shifting consumer demand.
“At TPG Telecom, the investments we make are designed to provide immediate benefit to our customers today, with an eye towards how we can unlock new opportunities, tomorrow,” said Rob James, Group Chief Digital & Information Officer of TPG Telecom. “Delivering improved value for our shareholders is essential for our success and the MATRIXX platform will enable us with the ability to rapidly innovate and experiment with new monetization models across all of our brands.”
Implemented as part of a full digital transformation program, MATRIXX Digital Commerce Platform enables TPG Telecom to be more commercially competitive, while also reducing costs associated with legacy infrastructure.
“We started with the ambition to consolidate multiple mobile rating platforms whilst still operating as Vodafone Hutchison Australia. Having merged with TPG Corporation to form TPG Telecom, using MATRIXX has further enabled us to ensure all our brands have access to a common rating platform. MATRIXX allows us to consolidate and transform 4G and 5G service monetization by moving to a single real-time platform that’s tightly integrated with our network,” said Easwaren Siva, General Manager Strategy & Architecture of TPG Telecom.
With the first phase completed, MATRIXX is now live for Vodafone branded prepaid services. Later phases of the transformation program will see TPG Telecom migrating mobile postpaid rating across their portfolio of brands, in addition to MVNO, wholesale and enable Standalone 5G charging.
“We are thrilled to be able to help bring TPG Telecom’s vision of improved commercial agility and greater customer experience,” said Glo Gordon, MATRIXX CEO. “Helping to transform how TPG Telecom monetizes today, while giving them a powerful and highly configurable monetization platform for their future innovation, speaks to the core of what we do best — empowering our customers, so that they can empower theirs.”
About TPG Telecom
TPG Telecom Limited was formed by the merger of Vodafone Hutchison Australia Pty Limited and TPG Corporation, formerly named TPG Telecom, on 13 July 2020. The merger brought together two highly complementary businesses, creating the leading challenger full-service telecommunications provider in Australia.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS) enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005060/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom